Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma | i3Health

i3Health has developed a dual part education activity for pharmacists on Multiple myeloma with special guest Joseph A. Kalis, PharmD, BCOP and Ambulatory Oncology Pharmacy Specialist. 

Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification. 

Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Module 1 of this continuing pharmacy education (CPE)–approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.